These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20177133)

  • 1. PTH increases jaw mineral density in a rabbit model of osteoporosis.
    Bellido M; Lugo L; Castañeda S; Roman-Blas JA; Rufián-Henares JA; Navarro-Alarcón M; Largo R; Herrero-Beaumont G
    J Dent Res; 2010 Apr; 89(4):360-5. PubMed ID: 20177133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTH [1-34] enhances bone response around titanium implants in a rabbit model of osteoporosis.
    Almagro MI; Roman-Blas JA; Bellido M; Castañeda S; Cortez R; Herrero-Beaumont G
    Clin Oral Implants Res; 2013 Sep; 24(9):1027-34. PubMed ID: 22626278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parathyroid hormone and its effects on dental tissues.
    Aggarwal P; Zavras A
    Oral Dis; 2012 Jan; 18(1):48-54. PubMed ID: 21895887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of osteoporosis with parathyroid hormone].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2008 Jan; 128(1):39-41. PubMed ID: 18183056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
    Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
    J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss.
    Tomimori Y; Mori K; Koide M; Nakamichi Y; Ninomiya T; Udagawa N; Yasuda H
    J Bone Miner Res; 2009 Jul; 24(7):1194-205. PubMed ID: 19257825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
    Wada S; Fukawa T; Kamiya S
    Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An intact N terminus is required for the anabolic action of parathyroid hormone on adult female rats.
    Armamento-Villareal R; Ziambaras K; Abbasi-Jarhomi SH; Dimarogonas A; Halstead L; Fausto A; Avioli LV; Civitelli R
    J Bone Miner Res; 1997 Mar; 12(3):384-92. PubMed ID: 9076581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Potential use of parathyroid hormone (PTH) in the treatments for oral diseases].
    Tanaka S; Hata K; Yoneda T
    Clin Calcium; 2012 Jan; 22(1):75-82. PubMed ID: 22201102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis.
    Nemeth EF
    IDrugs; 2008 Nov; 11(11):827-40. PubMed ID: 18988128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anabolic treatment for osteoporosis: PTH treatment].
    Kaji H; Sugimoto T
    Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of parathyroid hormone as a therapy for osteoporosis.
    Rubin MR; Bilezikian JP
    Int J Fertil Womens Med; 2002; 47(3):103-15. PubMed ID: 12081255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of alendronate and intermittent parathyroid hormone on implant fixation in ovariectomized rats.
    Skripitz R; Johansson HR; Ulrich SD; Werner A; Aspenberg P
    J Orthop Sci; 2009 Mar; 14(2):138-43. PubMed ID: 19337803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
    Greenspan SL; Holland S; Maitland-Ramsey L; Poku M; Freeman A; Yuan W; Kher U; Gertz B
    Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticosteroid-induced osteoporosis in adult primiparous Göttingen miniature pigs: effects on bone mineral and mineral metabolism.
    Scholz-Ahrens KE; Delling G; Stampa B; Helfenstein A; Hahne HJ; Açil Y; Timm W; Barkmann R; Hassenpflug J; Schrezenmeir J; Glüer CC
    Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E385-95. PubMed ID: 17456640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intermittent administration of human parathyroid hormone on bone mineral density and arthritis in rats with collagen-induced arthritis.
    Fukata S; Hagino H; Okano T; Yamane I; Kameyama Y; Teshima R
    Arthritis Rheum; 2004 Dec; 50(12):4060-9. PubMed ID: 15593226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat.
    Zhou H; Shen V; Dempster DW; Lindsay R
    J Bone Miner Res; 2001 Jul; 16(7):1300-7. PubMed ID: 11450706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
    De Nijs RN
    Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.